News about 'Early Drug Development'

27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...
4 May 2017
Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis CAMBRIDGE, Mass., May 4, 2017—Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today...
7 Jan 2015
Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘ Verapamil...
14 Jul 2014
A new study published by Dr. Kyu Rhee ’s laboratory at the Weill Cornell Medical College details a potential mechanism driving Mycobacterium tuberculosis’ intrinsic resistance to antibiotics. Physicians and scientists have known for many years that tuberculosis is intrinsically resistant to...
27 May 2014
Dr. Iwao Ojima Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. His group recently published a paper in PLOS One entitled A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against...
22 Apr 2014
The drug SQ109, developed by Sequella for the treatment of tuberculosis, blocks key biochemical pathways in bacteria, fungi, and parasites. The multiple targets of SQ109 have been determined by researchers at the University of Illinois Urbana-Champaign. The researchers also created analogs of SQ109...
11 Mar 2014
Vadim Makarov et. al. Towards a new combination therapy for tuberculosis with next generation benzothiazinones . EMBO Molecular Medicine. 2014. March 1; 6(3). doi: 10.1002/emmm.201303575 A new antibiotic, labeled ‘PBTZ169’, has been shown to be effective against drug sensitive and MDR-tuberculosis...
5 Mar 2014
Richard E. Lee et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux . Nature Medicine. 2014. March 6; 20(152). doi:10.1038/nm.3458 Abstract: Although the classical antibiotic spectinomycin is a potent bacterial protein synthesis inhibitor, poor...
23 Jun 2013
We invite you to join us for the “Targets for Tomorrow” satellite workshop hosted by the WGND Biology/Targets Subgroup on Monday, July 22, 2013 from 2 p.m. to 4:30 p.m. at the Renaissance Tuscany Il Ciocco Resort , Lucca (Barga), Italy. The workshop is held in conjunction with the Gordon Conference...
22 May 2013
Vilchèze C, Hartman T, Weinrick B, and Jacobs W. Mycobacterium tuberculosis is extraordinarily sensitive to killing by a vitamin C-induced Fenton reaction . Nature Communications. 2013 May 21; 4(1881). doi:10.1038/ncomms2898 Abstract: Drugs that kill tuberculosis more quickly could shorten...
24 May 2012
For this week’s update, we highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Dooley KE, Mitnick C, Degroote MA, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N,...
26 Mar 2012
The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved...
19 Jan 2012
Click here for brochure. Vincent V, Rigouts L, Nduwamahoro E, Holmes B, Cunningham J, Guillerm M, Nathanson CM, Moussy F, De Jong B, Portaels F, Ramsay A. The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. Int J Tuberc Lung Dis. 2012 Jan;16(1):...
13 Dec 2011
Dr. Yossef Av-Gay Summary: Dr. Yossef Av-Gay , a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in the Proceedings of the National Academy of Sciences (PNAS) entitled “ Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA...
25 Jul 2011
Vilchèze C, Baughn AD, Tufariello J, Leung LW, Kuo M, Basler CF, Alland D, Sacchettini JC, Freundlich JS, Jacobs WR Jr. Novel Inhibitors of InhA Efficiently Kill Mycobacterium tuberculosis under Aerobic and Anaerobic Conditions. Antimicrob Agents Chemother. 2011 Aug;55(8):3889-98. Epub 2011 May 31...

Pages